Background: MIIP has 3 SEG (segments of low compositional complexity) domains, an RGD motif, and several potential phosphorylation sites. The C-terminal region of IGFBP2 interacts with a central 44-amino acid sequence of MIIP. MIIP inhibits glioma cells invasion and down-regulates adhesion- and motility-associated genes such as NFKB2 and ICAM1. It exhibits opposing effects to IGFBP2 on cell invasion. There are 2 named isoforms due to alternative splicing. Isoform 1 is expressed in brain but underexpressed in glioma tissues, at protein level. Isoform 2 is not detected in normal organs, but is expressed in gliomas with increasing levels with glioma progression. On the contrary, at protein level, isoform 2 is not detected in gliomas, suggesting that this isoform is unstable in glioma cells. Isoform 2 is degraded by the ubiquitin-proteasome pathway.
Description: Rabbit polyclonal to MIIP
Immunogen: KLH conjugated synthetic peptide derived from MIIP
Specificity: ·Reacts with Human, Mouse, Dog and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 43 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
